Medicina
Fachbereich
Beckman Research Institute
City of Hope, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von Beckman Research Institute (69)
2024
-
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial
Nature Medicine, Vol. 30, Núm. 1, pp. 271-278
-
Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study
Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 3, pp. 194-202
2023
-
A likelihood ratio approach for utilizing case-control data in the clinical classification of rare sequence variants: Application to BRCA1 and BRCA2
Human Mutation, Vol. 2023
-
Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry
Genome Medicine, Vol. 15, Núm. 1
-
Correction to: Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion (American Journal of Clinical Dermatology, (2023), 24, 1, (5-14), 10.1007/s40257-022-00732-w)
American Journal of Clinical Dermatology
-
Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel
Journal of Medical Genetics, Vol. 60, Núm. 12, pp. 1186-1197
-
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 35, pp. 5363-5375
-
Identifying unmet needs and challenges in the definition of a plaque in mycosis fungoides: An EORTC-CLTG/ISCL survey
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 4, pp. 680-688
-
Mechanism of action of chlormethine gel in mycosis fungoides
Journal of the European Academy of Dermatology and Venereology, Vol. 37, Núm. 9, pp. 1739-1748
-
Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
Annals of Oncology, Vol. 34, Núm. 10, pp. 885-898
-
Real-Life Barriers to Diagnosis of Early Mycosis Fungoides: An International Expert Panel Discussion
American Journal of Clinical Dermatology, Vol. 24, Núm. 1, pp. 5-14
-
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a KRAS G12C Mutation.
New England Journal of Medicine, Vol. 389, Núm. 8, pp. 710-721
2022
-
Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial
European Urology, Vol. 82, Núm. 3, pp. 283-292
-
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores
Journal of the National Cancer Institute, Vol. 114, Núm. 1, pp. 109-122
-
Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers
Communications biology, Vol. 5, Núm. 1, pp. 1061
-
Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))
European journal of human genetics : EJHG
-
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials
JTO Clinical and Research Reports, Vol. 3, Núm. 9
-
Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics
Blood Advances, Vol. 6, Núm. 3, pp. 920-930
-
Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study
British Journal of Sports Medicine, Vol. 56, Núm. 20, pp. 1157-1170
-
Polygenic risk modeling for prediction of epithelial ovarian cancer risk
European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362